Product Name :
L-Tyrosine
Description:
L-Tyrosine is a non-essential amino acid which can inhibit citrate synthase activity in the posterior cortex.
CAS:
60-18-4
Molecular Weight:
181.19
Formula:
C9H11NO3
Chemical Name:
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
Smiles :
N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
InChiKey:
OUYCCCASQSFEME-QMMMGPOBSA-N
InChi :
InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
L-Tyrosine is a non-essential amino acid which can inhibit citrate synthase activity in the posterior cortex.|Product information|CAS Number: 60-18-4|Molecular Weight: 181.19|Formula: C9H11NO3|Chemical Name: (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid|Smiles: N[C@@H](CC1=CC=C(O)C=C1)C(O)=O|InChiKey: OUYCCCASQSFEME-QMMMGPOBSA-N|InChi: InChI=1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 1 mg/mL (5.52 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.Bisdemethoxycurcumin Protocol |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|L-Tyrosine inhibits citrate synthase activity in the posterior cortex (2.0 and 4.0 mM), malate dehydrogenase is not altered by L-Tyrosine and succinate dehydrogenase is increased in the posterior cortex (0.1-4.0 mM), hippocampus (1.0-4.0 mM), striatum (4.0 mM) and liver (0.1-4.0 mM). When complex I activity is analyzed, inhibition is observed in hippocampus (4.0 mM). In addition to inhibition in the hippocampus, complex II also is inhibited in the posterior cortex (0.1-4.0 mM) and liver (1.0, 2.0 and 4.0 mM).Tween 80 Cancer For complex II–III, activity is not altered by L-Tyrosine, and complex IV activity has decreased in the posterior cortex (1.PMID:32191127 0-4.0 mM) following treatment with L-Tyrosine.|In Vivo:|The acute administration of L-Tyrosine inhibits the activity of citrate synthase in the posterior cortex and liver; however, in the striatum, the activity is increased. The results also demonstrate that acute administration of L-Tyrosine inhibits malate dehydrogenase and complex II, II–III and IV of the mitochondrial respiratory chain activity in the posterior cortex and liver of rats. The succinate dehydrogenase enzyme and complex I activity are inhibited in the posterior cortex and increased in the striatum. Furthermore, energy metabolism in the hippocampus is not amended by an acute administration of L-Tyrosine.|Products are for research use only. Not for human use.|